Use this article as a guide but substitute ovarian cancer stats and see what you come up with as a valuation for Prima? No where near Dendreon's valuation unfortunately. Approval in other markets outside the US would be a priority for Prima. US trials alone will stimulate some interest in the stock imo. Goodluck and Goodnight.
http://seekingalpha.com/instablog/415388-dan-rosenblum/4656-why-sales-estimates-for-provenge-are-too-low
if this works???, page-53
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 30.5¢ | $251.5K | 806.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 121215 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 2864 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |